Cytokinetics, Incorporated (CYTK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 56 | 70 | 95 | 8 | 18 | 88 | 71 | 150 |
| Operating profit | $m | -612 | -705 | ||||||
| Net profit | $m | -127 | -215 | -389 | -526 | -590 | -785 | -894 | -635 |
| EPS reported | $ | -6.54 | -7.22 | ||||||
| Operating cashflow per share | $ | -4.25 | -4.21 | ||||||
| Capex per share | $ | 0.21 | 0.19 | ||||||
| FCF per share | $ | -4.46 | -4.40 | ||||||
| Free cash flow | $m | -535 | -581 | ||||||
| Net debt | $m | 275 | -19 | ||||||
| Book value equity | $m | -660 | -173 | ||||||
| Book value per share | $ | -5.49 | -1.31 | ||||||
| Number of shares | m | 120.1 | 132.09 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -11.56 | -43.96 | ||||||
| P/S LTM | x | 86.62 | 107.47 | ||||||
| P/FCF LTM | x | -14.26 | -13.13 | ||||||
| EV/EBITDA LTM | x | -11.34 | -10.74 | ||||||
| EV/Sales LTM | x | 99.82 | 141.83 | ||||||
| Earnings Yield LTM | % | -10.29% | -9.31% | ||||||
| FCF Yield | % | -7.01% | -7.61% | ||||||
| Quality | |||||||||
| ROE | % | +119.00% | +163.98% | ||||||
| ROIC | % | -47.74% | -39.33% | ||||||
| Operating margin | % | -6.95% | -9.93% | ||||||
| Gross margin | % | +88.50% | +84.97% | ||||||
| FCF/Sales | % | -607.48% | -818.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +376.56% | +284.11% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.42 | -0.46 | ||||||
| Net Debt/EBITDA | x | -1.50 | -1.24 | ||||||
| EBIT/Net interest | x | -5.89 | -5.64 | ||||||
| Net debt/market cap | % | +15.17% | +12.68% | ||||||
| Net debt/Equity | x | -0.42 | 0.11 | ||||||
| Gross debt/equity | x | -1.95 | -7.32 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cytokinetics, Incorporated (CYTK)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free